Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-07265028 |
| Synonyms | |
| Therapy Description |
PF-07265028 selectively inhibits MAP4K1 (HPK1), potentially leading to enhanced antitumor immune response and increased tumor cell killing (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-07265028 | PF 07265028|PF07265028 | MAP4K1 Inhibitor 8 | PF-07265028 selectively inhibits MAP4K1 (HPK1), potentially leading to enhanced antitumor immune response and increased tumor cell killing (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05233436 | Phase I | PF-07265028 PF-06801591 + PF-07265028 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | Terminated | USA | 1 |